Earnings analysis of drugmakers' quarterly results, in-depth business analysis and the CompePharma View, ten new pieces every day.
With $5.8M in cash and about $0.7M in royalty revenue, Xenetic is pairing a Q1 2027 all-stock acquisition with a first DNase I CAR-T dosing, as peers fund through royalty sales, licences and divestments.
The strongest results this season came from extending assets already in market, through new labels, formulations and royalties, rather than from unproven launches. That strategy has a ceiling.
With $288M in cash and a runway into 2028, MacroGenics is using non-dilutive deals to bet on B7-H3 ADC MGC026, starting in head and neck cancer.
Revenue reached $832.5 million as Tyvaso DPI and Orenitram grew, but Thymmune-related R&D and a higher tax rate pushed net income down to $258.6 million.
Medicare's full-rate payment for EsoGuard is a milestone, but case-by-case coverage and a pending reconsideration show why payer access, not list price, decides the economics.
Record $216.3M revenue rose 3% as JORNAY PM and AZSTARYS filled much of the gap left by pain declines; adjusted EBITDA fell 9% and guidance was reaffirmed.
The UK regulator's Phase 1 finding is confined to one product market, and the parties plan to reuse the EC-agreed divestment. Pharma dealmakers can learn from that.
Longeveron, Theriva and Silence show how much optionality depends on when boards start thinking about the endgame. The best time is before the data arrive.
Theriva's divestment of its antibiotic-enzyme assets to Biossil Labs is small in dollars but fits a day of triage, licensing and consolidation among cash-constrained developers.
Revenue rose 14.9% to $221.6 million and adjusted EBITDA margin hit 23.1%, but GAAP losses widened on settlements as the VitalConnect deal closed and guidance rose.
Silence reported positive Phase 2 polycythemia vera data and $247.7M in cash while its sale to Merck KGaA is pending, a sharp contrast with the weaker end of biotech's deal market.
This week's deals show buyers paying for proof or proven sales, while assets stuck between the two are sold for parts or put up for sale.
After laromestrocel failed its primary endpoint in infant HLHS, Longeveron is seeking FDA input and weighing a sale or merger, a stark contrast with this week's better-funded deals.
Obsidian Therapeutics posted a $50.7M Q3 net loss after its Galera deal and $350M financing, with its amsoki-cel registration-enabling cohort now the main driver of value.
From TransMedics to Ultragenyx, the Q3 results separate businesses that pay for their plans from those that still ask investors to wait. Funding has become the strategy.
Tarsus reported 64% year-over-year growth for XDEMVY and a roughly 93% gross margin, while two acquisitions pushed the quarter deep into the red and reshaped the pipeline.
Kiora has taken ex-Asia rights to Senju's oral calpain inhibitor for retinal artery occlusion, an early-stage option that sits alongside a busy week of eye-care and licensing deals.
This week's licences in Japan, Australasia, ASEAN and the Mediterranean show small companies can fund and de-risk without selling the whole asset, provided they hold on to the rights that set the value.
Recorlev's 93% jump more than accounted for Xeris's 44% revenue growth in Q3, while Gvoke shrank and the company raised both its 2026 guidance and its 2030 outlook.
Q3 results split into companies whose current numbers carry the story and those leaning on the future tense. Long-range ambition is only worth what the near-term print backs up.
A Q3 beat-and-raise on BRIUMVI's U.S. business sets up a run of dosing-format catalysts, from subcutaneous Phase 3 data to a simplified IV start, while spending rises.
From Heron's asset sale to Frontage's Exton units and Japan-only licences, this week's deals cut assets into pieces. How the pieces are cut now matters as much as who buys them.
Organic revenue rose 4.7% as safety assessment volume and Manufacturing demand offset May divestitures; the company lifted 2026 revenue and non-GAAP EPS guidance.
Ocugen has out-licensed OCU400 for Australia, NZ and ASEAN before its Q1 2027 Phase 3 readout, part of a week of deals that put regional rights, portfolios and capacity on the table.
This week's deals share a feature that headlines skip: the value depends on a stretch of time between signing and closing, and leaders should manage that stretch like a project.
Revenue rose 32% to $1.025 billion in Q3, yet lumpy international orders and two acquired-R&D charges led the company to lower full-year revenue and non-GAAP EPS guidance.
Top lines are strong and guidance is rising, but GAAP and adjusted results are diverging in both directions. The companies that show the bridge will earn the credibility.
Q3 demand stayed solid with 400 net patient adds and full-year guidance was held, while higher royalties and an R&D milestone cut earnings and the 2027 legal and regulatory calendar looms.
Commercial-stage biotechs grabbed the headlines, but the earnings with the most forward information came from the company that sells to drug developers, not the ones selling to patients.
Third-quarter net sales of $431.3 million, up 50%, turned a $114.2 million loss into $55.4 million of net income, while the company is already investing for the cirrhosis market.
From Edesa to Charles River, the sticker price says little. Upfront cash, earn-outs and closing conditions show who is actually carrying the risk.
Perspective Therapeutics pairs FDA Fast Track for PSV359 with a Merck Keytruda agreement, while a busy deal week shows buyers paying for assets, capacity and regional rights.
ANI beat on growth and profit in Q3, but cut Cortrophin Gel guidance by $40 million at both ends, blaming specialty pharmacy capacity, while launching a roughly $560 million bid for Egetis.
Harmony, TG, Madrigal and BioMarin all paired strong quarters with dated plans to widen what their lead medicines can do. Investors should expect that pairing from every franchise.
VYJUVEK revenue rose 30% to $127.3M with a 94% gross margin, and Krystal authorized a $400M buyback, yet net income fell year on year and several readouts moved into 2027.
BioMarin's 32% jump and ANI's pursuit of Egetis show M&A now drives reported momentum. Leaders should separate what they built from what they bought.
Corcept's third-quarter revenue rose 64% to $340.5M as Lifyorli nearly doubled sequentially, but reiterated 2026 guidance of $1.1–1.2B leaves a wide range for Q4.
A Japan-only licence for anti-TLR4 antibody paridiprubart is worth over $140m on paper, but this week's other deals show where capital is actually being committed.
This season's strongest results come from companies leaning hard on a single franchise. That is a strategy, not an accident, and it deserves to be managed like one.
Q3 revenue of $133 million and record adjusted EBITDA of $98 million came with a second guidance raise, while quarterly LINZESS sales growth slowed to 3.2% on rebate reserves.
From Madrigal's patient base to Harmony's net adds, the strongest third quarters rest on volume that can be counted, and the industry should disclose more of it.
Acadia raised 2026 DAYBUE guidance to $505–$520 million as DAYBUE STIX drove growth, while lower R&D spending and a swing from a tax benefit to a tax charge shaped the bottom line.
This season's guidance moves, raised, narrowed or simply reiterated, say more about management confidence than the quarterly beats do, and the best ones are product-specific and tight.
Net product revenue of $323.8M and a non-GAAP operating profit of $22.9M came with a higher guidance floor, while Q4 DM1 and FSHD readouts will shape the pipeline story.
Third-quarter results from six commercial-stage biotechs show product revenue funding late-stage R&D, deals and buybacks without a capital-markets visit. Leaders should plan around that.
Revenue rose 29% to $1.3 billion and the company raised its 2026 outlook, but the quarter's receivables, the convertible financing and a flu launch constrained by contracting timing shape the story.
Across five reporters, the biggest product lines carried the quarter. Raised guidance came from established franchises, so the case for protecting and extending them is stronger than the launch narrative suggests.
Third-quarter revenue rose 39% to $493.0 million on 44% royalty growth, and Halozyme raised all four 2026 guidance ranges while securing a Dutch injunction against Merck's Keytruda Qlex.
Commercial results from Moderna, PTC, Sarepta, Acadia and Halozyme are strong. Each release also points to the clinical or regulatory event that will define what comes next.
A $50.0 million Novo milestone flattered nine-month results, but the Q3 story is a much smaller cost base and a pipeline now funded by Roche, Novo and Bristol Myers Squibb.
From Biogen's GAAP loss to Sarepta's operating swing, the gap between reported and adjusted results is now a leadership test. Companies that explain it plainly earn more trust than those that merely close it.
Greater China and new products offset supply constraints and generics erosion, and margins widened, but a GAAP tax-driven loss and a suspended Indian plant frame the Pacira-era story.
Halozyme, Moderna and Sarepta show that the strongest guidance revisions pair growth with cost discipline. Top-line momentum alone is no longer the headline.
A $275 million Takeda trigger on the MIMRYLO approval turned a $39.3 million loss into $220.0 million of net income, while ICOTYDE's royalty contribution is not broken out.
From Viatris to Protagonist, companies are returning cash and buying assets in the same release. The credible ones will be those that state the order of priority.
BeOne raised 2026 revenue guidance to $6.9-$7.0 billion on a quarter in which GAAP operating income rose 157%, with BRUKINSA's MANGROVE filing and ASH data the next catalysts.
The oncology biotech has paid undisclosed cash for Aqilion's ACR-525 and a preclinical PKCθ programme, owing no milestones or royalties, a structure that shifts all future risk onto Acrivon.
Halozyme, Protagonist and BeOne show that the best results come from owning scale or from holding well-written claims on someone else's. Leaders should audit which they have.
Third-quarter revenue rose 10% and full-year guidance moved up, but acquired IPR&D pushed Jazz to a GAAP loss as Xywav, Zepzelca and new launches offset a soft Epidiolex.
A SPAC merger valuing cannabinoid API supplier Brains Bioceutical at about $750 million pre-money shows how public-market access is being traded for scale, set against a week of niche, capital-sensitive deals.